ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0685

The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients

Lisa Mandl, Medha Barbhaiya, Robyn Lipschultz, Benjamin Swett, Myriam Lin, Agnes Cororaton, Dongmei Sun, Kethy Jules-elysee, Doruk Erkan and Friedrich Boettner, Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2022

Keywords: antiphospholipid syndrome, Arthroplasty, COVID-19

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Acute SARS-CoV-2 infection has been associated with antiphospholipid antibodies (aPL), though it is unclear if aPL contribute to the hypercoagulability seen with COVID19, or if these aPL persist. We evaluated patients undergoing elective total knee replacement (TKR), a procedure with known risks of thrombosis, and compared aPL positivity in those with and without previous SARS-CoV-2 infection.

Methods: We recruited patients with osteoarthritis undergoing TKR at a single center between 10/2020 and 10/2021. Patients were screened for previous SARS-CoV-2 infection with a serum nucleocapsid IgG, and a cohort was assembled matching SARS-CoV-2 IgG +ve patients on age (+/- 5 years), gender, and body mass index (BMI kg/m2 ≤ 35 vs. > 35) with SARS-CoV-2 IgG -ve patients without self-reported COVID19. aPL (lupus anticoagulant [LA], anticardiolipin antibodies [aCL] IgG/M/A, and anti-β2-glycoprotein-I [aβ2GPI] IgG/M/A] were performed pre-operatively on all subjects, and 6 weeks later in the SARS-CoV-2 IgG +ve cases.

Results: 156 subjects enrolled, (73 cases:73 controls), average age 63.2 years (SD 8.0), 53.4% women, BMI 31.9 kg/m2 (SD 6.0), 78.8% Caucasian. 46/73 (63%) SARS-CoV-2 IgG +ve cases reported COVID19 symptoms; time between COVID19 symptoms and TKR was 243.3 days, (range: 17 – 597). 21% of both groups were positive for at least one aPL; the most common aPL type/isotype was aCL IgM (11% in SARS-CoV-2 +ve and 15% in SARS CoV-2 -ve). Other aPL types/isotypes ranged between 1-3% in both groups. 58/73 (80%) SARS-CoV-2 +ve cases had 6-week follow-up; of the 12 aPL-positive/SARS-CoV-2 +ve cases re-assessed at 6 weeks, 6/12 (50%) had disappearance of aPL (See Table). Among SARS-CoV-2 IgG +ve cases, a higher proportion of those reporting ≥ 5 COVID19 symptoms at time of clinical infection had any positive aPL both pre-operatively (40% vs 29%) and at 6 weeks (50% vs 31%). There was one deep vein thrombosis in a SARS-CoV-2 IgG +ve case. There were no differences in pain or function at 6 weeks between the 6 SARS-CoV-2 IgG +ve cases who were +ve for aPL at baseline and remained +ve at 6 weeks, and those who became negative for aCL.

Conclusion: Regardless of previous SARS-CoV-2 infection, approximately one-fifth of patients undergoing elective TKR for osteoarthritis had positive aPL, mostly low level (20-39U) aCL IgM. Half of SARS-CoV-2 nucleocapsid IgG +ve /aPL-positive subjects became aPL negative at 6-weeks, and aCL status was not associated with pain or function at 6 weeks. These data contribute to our understanding of aCL prevalence, and suggest SARS-CoV-2 nucleocapsid IgG may not be associated with increased incidence of aCL.

Supporting image 1

Table 1

Supporting image 2

Table 2

Supporting image 3

Table 3


Disclosures: L. Mandl, Pfizer; M. Barbhaiya, None; R. Lipschultz, None; B. Swett, None; M. Lin, None; A. Cororaton, None; D. Sun, None; K. Jules-elysee, None; D. Erkan, None; F. Boettner, Smith and Nephew, Ortho Development.

To cite this abstract in AMA style:

Mandl L, Barbhaiya M, Lipschultz R, Swett B, Lin M, Cororaton A, Sun D, Jules-elysee K, Erkan D, Boettner F. The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-association-of-antiphospholipid-antibodies-with-previous-sars-cov-2-infection-among-elective-knee-replacement-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-antiphospholipid-antibodies-with-previous-sars-cov-2-infection-among-elective-knee-replacement-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology